Merck to buy rights to Chinese cancer drug
The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...
What separates KL-50 from other chemotherapy drugs is its remarkable selectivity ... it was fundraising,” Lin told the News ...
Merck, known as MSD outside the United ... HIV and their communities for the collaboration that made today’s approval possible.” Both drugs, administered orally once daily, are indicated ...
After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...
The Motley Fool on MSN13d
Is Merck Stock a Buy?That made it the largest contributor to Merck's total quarterly sales of $16.1 billion. Ongoing clinical trials and ...
It's worth noting that the agreement has been forged a few months after Merck suffered a setback in its attempt to secure FDA approval for a potentially first-in-class drug for chronic cough ...
Merck, a leading science and technology company, today announced a € 70 million expansion of its ADC manufacturing ...
but lacks a ready-made Keytruda replacement. Investors should monitor R&D updates closely, as Merck's future hinges on new drug developments amid looming patent expirations. Keytruda is now ...
The drug has played an instrumental role in driving ... for treating adjuvant melanoma and non-small cell lung cancer. Merck made meaningful regulatory and clinical progress this year across ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback